Cancer Biomarkers

Cancer Biomarkers Market Outlook

The global cancer biomarkers market is poised for significant growth, with an estimated value of USD 23.6 billion in 2025, projected to reach USD 43.9 billion by 2035, representing a compound annual growth rate (CAGR) of 6.7%. The increasing prevalence of cancer, coupled with the rising demand for early diagnosis and personalized treatments, is driving the market's expansion. Moreover, advancements in technology and research methodologies, such as gene sequencing and molecular diagnostics, are enhancing the accuracy of cancer detection. The growing emphasis on preventive medicine and the integration of biomarkers in drug development processes are also contributing to market growth. As healthcare providers continue to adopt innovative diagnostic tools, the cancer biomarkers market is set to thrive in the upcoming years.

Growth Factor of the Market

The growth of the cancer biomarkers market can be attributed to several key factors. Firstly, the rising incidence of various types of cancer across the globe necessitates the development of effective diagnostic and treatment solutions, which in turn drives the demand for cancer biomarkers. Secondly, advancements in biotechnology and genomics have led to the discovery of novel biomarkers that are crucial for early cancer detection and monitoring treatment responses. Thirdly, the increasing focus on personalized medicine has spurred healthcare providers to utilize biomarkers for tailoring treatment regimens to individual patients. Furthermore, government initiatives and funding aimed at cancer research and biomarker development are fostering innovation in this field. Lastly, a growing awareness among patients regarding the benefits of early diagnosis and preventive healthcare is propelling the demand for cancer biomarker tests, creating a favorable market environment.

Key Highlights of the Market

• The global cancer biomarkers market is expected to grow at a CAGR of 6.7% from 2025 to 2035.
• Technological advancements in molecular diagnostics are enhancing the detection rates and accuracy of biomarkers.
• Personalized medicine is gaining traction, with biomarkers playing a critical role in tailoring treatment plans.
• North America holds the largest share of the cancer biomarkers market due to advanced healthcare infrastructure.
• Collaboration between academic institutions and biotech companies is fostering innovation in biomarker research and development.

By Product Type

Genetic Biomarkers:

Genetic biomarkers are critical indicators derived from an individual's genetic makeup, playing a pivotal role in cancer diagnosis, treatment, and prognosis. They are particularly useful in identifying specific gene mutations that predispose individuals to certain types of cancer, thereby facilitating early detection and preventive measures. The growth of next-generation sequencing technologies has significantly enhanced the identification of genetic biomarkers, enabling clinicians to provide personalized treatment strategies based on a patient's genetic profile. This segment is anticipated to witness substantial growth as the demand for precision medicine escalates, further driving research into genetic alterations associated with various cancers.

Protein Biomarkers:

Protein biomarkers are proteins whose presence, absence, or altered levels can indicate the presence of cancer. These biomarkers are widely used in clinical settings for diagnostic purposes, as they can be readily measured in bodily fluids, such as blood and urine. The protein biomarkers market is driven by the increasing adoption of proteomics technologies, which allow for the comprehensive analysis of protein expressions in cancer patients. This segment is essential for disease monitoring and assessing treatment efficacy, making it a focal point for ongoing research and development. The market for protein biomarkers is expected to grow steadily as novel protein-based assays continue to emerge.

Glycoprotein Biomarkers:

Glycoprotein biomarkers, which are proteins with carbohydrate moieties, are emerging as crucial indicators in cancer diagnostics and therapeutics. These biomarkers play a significant role in cell-cell interactions and immune responses, making them valuable in understanding tumor behavior and progression. The glycoprotein biomarkers segment is gaining traction due to advancements in glycomics technologies that facilitate the identification and characterization of glycoproteins associated with cancers. As more research elucidates the role of glycoproteins in cancer biology, their application in clinical settings is expected to expand, contributing to the market's growth.

Hormone Biomarkers:

Hormone biomarkers, including hormones and their receptors, are vital in the diagnosis and management of hormone-sensitive cancers, such as breast and prostate cancer. These biomarkers assist in assessing tumor characteristics and determining the most effective treatment options. The increasing prevalence of hormone-related cancers is driving the demand for hormone biomarker testing, particularly in personalized medicine. This segment is bolstered by advancements in assay technologies that allow for accurate hormone level detection. The hormone biomarkers market is anticipated to grow as healthcare providers increasingly utilize these markers to guide treatment decisions and monitor disease progression.

Others:

This category encompasses various biomarkers that do not fit into the aforementioned types, including metabolites and lipid biomarkers. These markers are gaining attention for their potential in early cancer detection and monitoring treatment responses. The ongoing research into novel biomarker discovery is expected to drive growth in this segment, as scientists investigate different biological pathways and their relationships with cancer. The integration of multi-omics approaches is likely to enhance the understanding of cancer biology, which will further expand the market for these alternative biomarkers, providing valuable insights into tumor dynamics and patient outcomes.

By Application

Diagnostics:

The diagnostics application segment of the cancer biomarkers market is fundamental in identifying cancer at early stages, which greatly enhances treatment efficacy and patient survival rates. Biomarkers used in diagnostics help in distinguishing cancerous tissues from benign ones, guiding clinicians in making informed decisions regarding treatment pathways. With technological advancements in biomarker testing methodologies, such as liquid biopsies and imaging techniques, this segment continues to gain traction. The increasing prevalence of cancer and the growing emphasis on early detection and prevention strategies are expected to bolster the diagnostics segment significantly in the coming years.

Prognostics:

Prognostic biomarkers provide valuable information about the likely progression of cancer in a patient, which is crucial for determining the appropriate therapeutic approach. These biomarkers aid in predicting disease outcomes, identifying high-risk patients, and tailoring treatment plans accordingly. The prognostics application segment is witnessing growth due to the rising demand for personalized medicine, where treatment regimens are customized based on an individual’s prognosis. As research continues to unveil new prognostic indicators and their clinical significance, this segment is likely to expand, providing valuable insights to healthcare professionals in managing cancer patients effectively.

Research:

The research application segment of the cancer biomarkers market encompasses extensive studies aimed at understanding cancer biology, its progression, and the development of novel therapeutic strategies. Biomarkers play a pivotal role in research by allowing scientists to investigate molecular changes associated with cancer initiation and progression. This segment is expected to grow as funding for cancer research initiatives increases and collaboration between academic institutions and biotech companies intensifies. The ongoing quest for novel biomarkers that can facilitate early detection and treatment optimization is driving significant advancements in this area, ultimately enhancing the landscape of cancer research.

Personalized Medicine:

Personalized medicine, which tailors treatment strategies based on individual patient characteristics, is increasingly reliant on cancer biomarkers. This application segment allows for a more targeted approach in cancer treatment, where therapies are selected based on the unique molecular profile of a patient's tumor. The growing emphasis on personalized medicine is transforming cancer care, leading to improved patient outcomes and reduced treatment-related side effects. The integration of biomarkers in clinical practice is expected to drive growth in this segment, as healthcare providers seek to provide more effective, customized therapies to their patients.

Therapeutics:

The therapeutics application segment involves the use of cancer biomarkers in the development and monitoring of targeted therapies. Biomarkers are essential for identifying suitable candidates for specific treatments, ensuring that patients receive therapies most likely to benefit them. This segment is gaining momentum as the pharmaceutical industry increasingly focuses on drug development strategies that incorporate biomarkers to predict treatment responses. The rise of immunotherapy and targeted therapies, along with regulatory advancements that encourage the use of biomarkers in clinical trials, is expected to drive growth in the therapeutics segment significantly.

By Detection Type

Blood Tests:

Blood tests are a commonly utilized detection method for cancer biomarkers, providing a non-invasive means of identifying the disease. These tests detect circulating tumor cells, cell-free DNA, and specific proteins associated with cancer, making them invaluable for early diagnosis and regular monitoring. The increasing popularity of liquid biopsies, which analyze biomarkers from blood samples, is driving the growth of this segment. Blood tests offer significant advantages, including ease of administration and minimal patient discomfort, further contributing to their widespread acceptance in clinical practice. As research progresses in this area, the blood tests segment is expected to expand, providing critical insights into cancer management.

Imaging Tests:

Imaging tests play a significant role in the detection and diagnosis of cancer biomarkers, as they provide visual representations of tumors and associated changes in body tissues. Techniques such as MRI, CT scans, and PET scans are employed to identify tumor locations, sizes, and metabolic activity. The imaging tests segment is expected to grow with advancements in imaging technology that enhance resolution and accuracy, enabling earlier detection of cancerous abnormalities. Integration of imaging biomarkers with traditional biomarkers further improves diagnostic precision, making this segment pivotal in the overall cancer biomarkers market.

Biopsy:

Biopsy remains the gold standard for cancer diagnosis, involving the extraction of tissue samples for histological examination. This detection type provides definitive information regarding tumor characteristics, genetic mutations, and biomarker expression levels. The biopsy segment is crucial for accurate cancer diagnosis and understanding tumor biology. Although invasive, advancements in techniques such as fine-needle aspiration and core needle biopsy have made the procedure more accessible and safer for patients. As research continues to identify novel biomarkers through biopsy analysis, this segment is expected to sustain its importance in the cancer biomarkers market.

Molecular Tests:

Molecular tests are increasingly utilized to detect cancer biomarkers at a genetic and molecular level, providing insights into an individual's cancer risk and treatment response. These tests analyze DNA, RNA, or proteins to identify specific mutations or alterations associated with cancer. The growing focus on precision medicine is driving demand for molecular testing, as it enables tailored treatment strategies based on molecular profiles. The molecular tests segment is anticipated to witness significant growth as advancements in technology continue to enhance testing capabilities and accessibility, paving the way for more personalized cancer care.

Others:

This category includes various detection methods that do not fall under the primary types mentioned earlier. Techniques such as breath tests, urine tests, and novel imaging techniques are gaining traction in the cancer biomarkers market. As research explores alternative detection methods, this segment is expected to grow, driven by innovations that enhance the ability to identify cancer biomarkers in non-invasive ways. The ongoing quest for less invasive and more accurate detection methods is likely to propel the growth of this segment, complementing the established detection types.

By Cancer Type

Breast Cancer:

Breast cancer is one of the most prevalent cancer types, making it a significant focus for the cancer biomarkers market. Biomarkers such as HER2, estrogen receptors, and progesterone receptors are critical for diagnosing and determining treatment strategies. The increasing incidence of breast cancer globally is driving demand for effective diagnostic tools, which consequently fuels growth in the breast cancer biomarker segment. Additionally, advances in screening technologies and targeted therapies are enhancing the focus on breast cancer biomarkers, as they play a pivotal role in personalized treatment approaches.

Lung Cancer:

Lung cancer is another major area of concern in the cancer biomarkers market, with biomarkers such as EGFR, ALK, and KRAS mutations being critical for diagnosis and treatment decisions. The high mortality rate associated with lung cancer emphasizes the need for early detection and effective biomarker-based interventions. The lung cancer biomarker segment is expected to grow significantly as research continues to uncover novel biomarkers and targeted therapies. The increasing prevalence of lung cancer, particularly among smokers and individuals exposed to environmental pollutants, further drives the demand for lung cancer biomarker tests.

Colorectal Cancer:

Colorectal cancer is a leading cause of cancer-related deaths worldwide, underscoring the importance of early detection and accurate diagnosis through biomarkers. Biomarkers such as CEA (carcinoembryonic antigen) and MSI (microsatellite instability) are essential for evaluating disease progression and treatment responses. The growing awareness of colorectal cancer screening and the integration of biomarkers into diagnostic pathways are expected to boost this segment. Additionally, advancements in non-invasive screening methods, such as stool DNA tests, are further enhancing the colorectal cancer biomarker market.

Prostate Cancer:

Prostate cancer is prevalent among men, and biomarkers such as PSA (prostate-specific antigen) are crucial for its diagnosis and management. The prostate cancer biomarker segment is witnessing growth due to the rising incidence of the disease and advancements in biomarker research that provide insights into tumor aggressiveness and treatment options. As more personalized approaches to prostate cancer management are developed, the demand for biomarkers that predict treatment responses and outcomes is expected to increase. Ongoing research into new biomarkers is likely to enhance clinical decision-making in prostate cancer care.

Others:

This segment encompasses various cancer types outside the primary categories, including cancers of the kidney, bladder, liver, and others. The increasing recognition of the role of biomarkers in diagnosing and treatment planning for these cancers is driving growth in this segment. Research into novel biomarkers for lesser-known cancers is gaining momentum, fueled by advancements in biotechnology and genomic research. As the understanding of tumor biology broadens, the demand for biomarkers in these cancer types is expected to rise, contributing to the overall expansion of the cancer biomarkers market.

By Region

The regional analysis of the cancer biomarkers market reveals significant variations in market dynamics and growth potential. North America holds the largest market share, primarily due to its advanced healthcare infrastructure, high prevalence of cancer, and increasing adoption of innovative diagnostic techniques. The region accounted for approximately USD 10.5 billion of the total market share in 2025 and is expected to maintain a CAGR of 7% through 2035. This growth is supported by ongoing investments in research and development, as well as the presence of key players in the market. The regulatory environment in the United States also facilitates faster approval processes for new biomarker tests, further contributing to market expansion.

Europe is the second-largest market for cancer biomarkers, driven by rising cancer incidence rates, growing awareness about early diagnosis, and advancements in healthcare technology. The European market is projected to reach approximately USD 8 billion by 2035, growing at a CAGR of 6% during the forecast period. The rising emphasis on personalized medicine and the adoption of molecular diagnostics in countries such as Germany, France, and the UK are boosting the demand for cancer biomarkers. Additionally, increasing collaborations between academic institutions and biotech firms in Europe are enhancing research efforts, leading to the discovery of novel biomarkers and their applications in clinical practices.

Opportunities

The cancer biomarkers market presents numerous opportunities for stakeholders, particularly in the realm of technological advancements. The evolution of next-generation sequencing (NGS) technologies is revolutionizing the identification and validation of novel cancer biomarkers. These advancements enable researchers to analyze genetic variations and epigenetic changes comprehensively, paving the way for personalized medicine approaches. Companies specializing in biomarker development can leverage NGS platforms to create more effective diagnostic tools and therapeutic strategies tailored to individual patient profiles. Additionally, the integration of artificial intelligence (AI) and machine learning in biomarker research holds immense potential for accelerating the discovery process and optimizing clinical outcomes, presenting a substantial opportunity for market players.

Furthermore, as healthcare systems globally shift toward value-based care, there is an increasing emphasis on preventive measures and early cancer detection. This trend is expected to drive demand for innovative biomarker-based tests that provide accurate and rapid results. The growing awareness among patients regarding the benefits of early diagnosis and personalized treatment options is also creating opportunities for companies to develop and commercialize advanced biomarker assays. Additionally, collaborations between pharmaceutical companies and diagnostic firms can facilitate the development of companion diagnostics, which enhance the efficacy of targeted therapies, thereby creating a synergistic potential within the cancer biomarkers market.

Threats

Despite the promising growth trajectory of the cancer biomarkers market, several threats could impede progress. One major challenge is the stringent regulatory environment surrounding the approval and commercialization of biomarker-based tests. Regulatory bodies such as the FDA and EMA have established rigorous requirements for the validation and clinical utility of biomarkers, which can prolong the time-to-market for new diagnostic tools. This regulatory complexity can deter small and mid-sized companies from investing in biomarker research and development, limiting innovation in the market. Furthermore, reimbursement issues pose another significant threat, as payers may be hesitant to cover new biomarker tests, particularly in cases where clinical utility is not well-established. This uncertainty can hinder market growth and limit patient access to essential diagnostic tools.

Moreover, the market faces threats from fierce competition, as numerous players are vying for a share in the cancer biomarkers space. The growing number of biomarker research initiatives and the rapid pace of technological advancements can lead to market saturation and increased pricing pressures. Additionally, the emergence of alternative diagnostic technologies, such as imaging and liquid biopsy methods, may divert attention away from traditional biomarker assays, posing a threat to established players in the market. As the landscape evolves, companies must innovate continuously and adapt to changing market dynamics to remain competitive.

Competitor Outlook

• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Abbott Laboratories
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Siemens Healthineers
• F. Hoffmann-La Roche AG
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• Genomic Health, Inc.
• Agilent Technologies, Inc.
• Hoffmann-La Roche
• PerkinElmer, Inc.

The competitive landscape of the cancer biomarkers market is characterized by a mix of established players and emerging companies, each striving to make significant advancements in biomarker research and development. Leading companies such as Roche Diagnostics and Thermo Fisher Scientific are at the forefront, leveraging their extensive product portfolios and technological expertise to offer innovative solutions in the cancer biomarkers space. These organizations have made significant investments in R&D, enabling them to develop cutting-edge diagnostic tests and maintain a competitive edge. Furthermore, collaborations and partnerships with academic institutions and healthcare providers are fostering innovation and facilitating the discovery of novel biomarkers, driving overall market growth.

Emerging players in the cancer biomarkers market are also gaining traction, particularly those focused on niche applications and specific cancer types. For instance, companies like Myriad Genetics and Exact Sciences are pioneering genetic tests that provide valuable insights into cancer risk assessment and personalized treatment options. Their commitment to research and innovation positions them as key competitors in the biomarker landscape. Additionally, advancements in artificial intelligence and machine learning are enabling these companies to optimize biomarker discovery processes, further enhancing their competitiveness in the market.

Furthermore, collaboration among industry stakeholders is increasingly prevalent, as companies recognize the potential benefits of working together to advance cancer biomarker research. Strategic partnerships between diagnostic companies and biopharmaceutical firms aim to develop companion diagnostics that enhance the efficacy of targeted therapies. This collaborative approach is likely to shape the future of the cancer biomarkers market, as it facilitates the development of innovative solutions that improve patient outcomes. Overall, the competitive landscape is dynamic, with both established firms and emerging players actively contributing to the continued evolution of cancer biomarker applications.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 QIAGEN N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Illumina, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hoffmann-La Roche
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Genomic Health, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Myriad Genetics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 F. Hoffmann-La Roche AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Agilent Technologies, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bio-Rad Laboratories, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Exact Sciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cancer Biomarkers Market, By Application
    • 6.1.1 Diagnostics
    • 6.1.2 Prognostics
    • 6.1.3 Research
    • 6.1.4 Personalized Medicine
    • 6.1.5 Therapeutics
  • 6.2 Cancer Biomarkers Market, By Cancer Type
    • 6.2.1 Breast Cancer
    • 6.2.2 Lung Cancer
    • 6.2.3 Colorectal Cancer
    • 6.2.4 Prostate Cancer
    • 6.2.5 Others
  • 6.3 Cancer Biomarkers Market, By Product Type
    • 6.3.1 Genetic Biomarkers
    • 6.3.2 Protein Biomarkers
    • 6.3.3 Glycoprotein Biomarkers
    • 6.3.4 Hormone Biomarkers
    • 6.3.5 Others
  • 6.4 Cancer Biomarkers Market, By Detection Type
    • 6.4.1 Blood Tests
    • 6.4.2 Imaging Tests
    • 6.4.3 Biopsy
    • 6.4.4 Molecular Tests
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Cancer Biomarkers Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cancer Biomarkers market is categorized based on

By Product Type

• Genetic Biomarkers
• Protein Biomarkers
• Glycoprotein Biomarkers
• Hormone Biomarkers
• Others

By Application

• Diagnostics
• Prognostics
• Research
• Personalized Medicine
• Therapeutics

By Detection Type

• Blood Tests
• Imaging Tests
• Biopsy
• Molecular Tests
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Abbott Laboratories
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Siemens Healthineers
• F. Hoffmann-La Roche AG
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• Genomic Health, Inc.
• Agilent Technologies, Inc.
• Hoffmann-La Roche
• PerkinElmer, Inc.